A Phase 3 interventional study of Tirzepatide and Placebo in Obesity, Overweight and Metabolism and Nutrition Disorder, sponsored by Eli Lilly and Company. Completed at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-19.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 29th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 10th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 65th largest by enrollment of the 117 interventional ones that give a count, is one of 8 that started in 2021, is one of 51 in phase 3, and was the 12th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight.
The main purpose is to learn more about how tirzepatide affects body weight.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
Drug: Tirzepatide
Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
Drug: Tirzepatide
Participants received matching placebo SC QW.
Drug: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Mean Percent Change From Baseline in Body Weight
Mean Percent Change from Baseline in Body Weight. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + Sex + Presence of Comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Percentage of Participants who Achieve ≥5% Body Weight Reduction. A logistic regression model was used for this analysis.
Time frame: Week 52
Mean Change From Baseline in Body Weight
Mean Change from Baseline in Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 20
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Percentage of Participants who Achieve ≥10% Body Weight Reduction. A logistic regression model was used for this analysis.
Time frame: Week 52
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Percentage of Participants who Achieve ≥15% Body Weight Reduction. A logistic regression model was used for this analysis.
Time frame: Week 52
Mean Change From Baseline in Waist Circumference
Mean Change from Baseline in Waist Circumference. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Absolute Body Weight
Mean Change from Baseline in Absolute Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Body Mass Index (BMI)
Mean Change from Baseline in BMI. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Hemoglobin A1c (HbA1c)
Mean Change from Baseline in HbA1c. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Fasting Glucose (FSG)
Mean Change from Baseline in FSG. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score
The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Information from these 8 domains is further aggregated into 2 health component summary scores: Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths. Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. LS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. LS mean was determined using ANCOVA model with Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)
LS mean was determined using MMRM model with Variable = Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)
LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
LS mean was determined using MMRM model using log (Actual measurement/Baseline) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)
LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 10 mg and 15 mg)
LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg)
LS mean was determined using MMRM model with log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 52
| Milestone | 10 Milligrams (mg) Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Started | 70 | 71 | 69 |
| Received at least one dose | 70 | 71 | 69 |
| Completed | 69 | 67 | 65 |
| Not completed | 1 | 4 | 4 |
| Withdrew: Withdrawal by subject | 0 | 3 | 4 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
Mean Percent Change from Baseline in Body Weight. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + Sex + Presence of Comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percent change | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Percent Change From Baseline in Body Weight | -14.4 ± 0.98 | -19.9 ± 1.01 | -2.4 ± 1.00 |
Percentage of Participants who Achieve ≥5% Body Weight Reduction. A logistic regression model was used for this analysis.
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥5% Body Weight Reduction | 91.43 | 92.65 | 29.41 |
Mean Change from Baseline in Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| kilograms (kg) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Body Weight | -9.0 ± 0.59 | -11.1 ± 0.61 | -1.8 ± 0.60 |
Percentage of Participants who Achieve ≥10% Body Weight Reduction. A logistic regression model was used for this analysis.
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥10% Body Weight Reduction | 70.0 | 83.82 | 14.71 |
Percentage of Participants who Achieve ≥15% Body Weight Reduction. A logistic regression model was used for this analysis.
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥15% Body Weight Reduction | 48.57 | 72.06 | 2.94 |
Mean Change from Baseline in Waist Circumference. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| centimeters (cm) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Waist Circumference | -11.9 ± 0.83 | -16.4 ± 0.85 | -2.7 ± 0.84 |
Mean Change from Baseline in Absolute Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| kilograms (kg) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Absolute Body Weight | -13.1 ± 0.93 | -18.1 ± 0.95 | -2.1 ± 0.94 |
Mean Change from Baseline in BMI. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| kilograms per metres squared (kg/m^2) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Body Mass Index (BMI) | -4.7 ± 0.29 | -6.4 ± 0.30 | -0.8 ± 0.30 |
Mean Change from Baseline in HbA1c. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percentage of HbA1c | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Hemoglobin A1c (HbA1c) | -0.34 ± 0.032 | -0.35 ± 0.033 | 0.03 ± 0.033 |
Mean Change from Baseline in FSG. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimoles per liter (mmol/L) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Fasting Glucose (FSG) | -0.25 ± 0.050 | -0.33 ± 0.052 | 0.22 ± 0.051 |
The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Information from these 8 domains is further aggregated into 2 health component summary scores: Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths. Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. LS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables.
| Score on a scale | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score | 2.0 ± 0.40 | 1.9 ± 0.42 | 0.8 ± 0.41 |
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. LS mean was determined using ANCOVA model with Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables.
| Score on a scale | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score | 11.2 ± 1.44 | 12.0 ± 1.48 | 3.5 ± 1.48 |
LS mean was determined using MMRM model with Variable = Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimeters of Mercury (mmHg) | Tirzepatide Pooled Analysis | Placebo |
|---|---|---|
| Mean Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -6.1 ± 0.62 | -1.3 ± 0.88 |
LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimeters of Mercury (mmHg) | Tirzepatide Pooled Analysis | Placebo |
|---|---|---|
| Mean Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -9.6 ± 0.87 | -3.5 ± 1.24 |
LS mean was determined using MMRM model using log (Actual measurement/Baseline) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimoles per liter (mmol/L) | Tirzepatide Pooled Analysis | Placebo |
|---|---|---|
| Mean Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -0.37 ± 0.055 | -0.06 ± 0.085 |
LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimoles per liter (mmol/L) | Tirzepatide Pooled Analysis | Placebo |
|---|---|---|
| Mean Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg) | 0.12 ± 0.017 | 0.03 ± 0.023 |
LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimoles per liter (mmol/L) | Tirzepatide Pooled Analysis | Placebo |
|---|---|---|
| Mean Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -0.17 ± 0.056 | -0.11 ± 0.081 |
LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimoles per liter (mmol/L) | Tirzepatide Pooled Analysis | Placebo |
|---|---|---|
| Mean Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -0.28 ± 0.019 | -0.03 ± 0.042 |
LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimoles per liter (mmol/L) | Tirzepatide Pooled Analysis | Placebo |
|---|---|---|
| Mean Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -0.63 ± 0.045 | -0.05 ± 0.099 |
LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimoles per liter (mmol/L) | Tirzepatide Pooled Analysis | Placebo |
|---|---|---|
| Mean Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -0.16 ± 0.013 | -0.10 ± 0.023 |
LS mean was determined using MMRM model with log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| milliunits per liter (mU/L) | Tirzepatide Pooled Analysis | Placebo |
|---|---|---|
| Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -6.5 ± 0.42 | -0.2 ± 1.09 |
Collected over Baseline Through Safety Follow-Up (Up To Week 56). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 mg Tirzepatide | 0/70 (0%) | 3/70 (4.3%) | 61/70 (87.1%) |
| 15 mg Tirzepatide | 0/71 (0%) | 8/71 (11.3%) | 56/71 (78.9%) |
| Placebo | 0/69 (0%) | 6/69 (8.7%) | 39/69 (56.5%) |
| Event | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Abortion inducedSurgical and medical procedures | 0/35 | 0/35 | 1/33 |
| Uterine polypReproductive system and breast disorders | 1/35 | 0/35 | 0/33 |
| EpididymitisInfections and infestations | 0/35 | 0/36 | 1/36 |
| Large intestine polypGastrointestinal disorders | 0/70 | 0/71 | 1/69 |
| Covid-19Infections and infestations | 0/70 | 0/71 | 1/69 |
| Urinary tract infectionInfections and infestations | 0/70 | 0/71 | 1/69 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/70 | 0/71 | 1/69 |
| Cervical radiculopathyNervous system disorders | 0/70 | 0/71 | 1/69 |
| Medical device removalSurgical and medical procedures | 0/70 | 0/71 | 1/69 |
| Supraventricular tachycardiaCardiac disorders | 1/70 | 0/71 | 0/69 |
| Event | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 28/70 | 29/71 | 6/69 |
| NauseaGastrointestinal disorders | 21/70 | 23/71 | 4/69 |
| Decreased appetiteMetabolism and nutrition disorders | 19/70 | 20/71 | 8/69 |
| Upper respiratory tract infectionInfections and infestations | 16/70 | 17/71 | 12/69 |
| VomitingGastrointestinal disorders | 8/70 | 14/71 | 3/69 |
| Abdominal distensionGastrointestinal disorders | 13/70 | 9/71 | 1/69 |
| HyperuricaemiaMetabolism and nutrition disorders | 3/70 | 5/71 | 8/69 |
| GastroenteritisInfections and infestations | 8/70 | 2/71 | 0/69 |
| Vaginal infectionInfections and infestations | 1/35 | 2/35 | 3/33 |
| Hepatic function abnormalHepatobiliary disorders | 3/70 | 1/71 | 6/69 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Mean | 34.70 ± 7.24 | 35.80 ± 9.33 | 37.80 ± 10.24 | 36.10 ± 9.07 |
| Sex: Female, Male(Participants) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Female | 35 | 35 | 33 | 103 |
| Male | 35 | 36 | 36 | 107 |
| Race (NIH/OMB)(Participants) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 70 | 71 | 69 | 210 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| China | 70 | 71 | 69 | 210 |
| Body Weight(kilograms (kg)) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Mean | 92.2 ± 16.2 | 91.3 ± 16.2 | 92.0 ± 15.8 | 91.8 ± 16.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2021 to primary completion in Dec 2022, 15 months.
Results were first posted in Jan 2024, 1 year after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 15 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide